Cargando…

Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia

Escape from chemotherapy-induced apoptosis is a hallmark of drug resistance in cancer. The recent identification of alternative programmed cell death pathways opens up for possibilities to circumvent the apoptotic blockade in drug resistant cancer and eliminate malignant cells. Indeed, we have recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezzatesta, Caterina, Bornhauser, Beat C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433701/
https://www.ncbi.nlm.nih.gov/pubmed/30941349
http://dx.doi.org/10.3389/fcell.2019.00040
_version_ 1783406324413890560
author Mezzatesta, Caterina
Bornhauser, Beat C.
author_facet Mezzatesta, Caterina
Bornhauser, Beat C.
author_sort Mezzatesta, Caterina
collection PubMed
description Escape from chemotherapy-induced apoptosis is a hallmark of drug resistance in cancer. The recent identification of alternative programmed cell death pathways opens up for possibilities to circumvent the apoptotic blockade in drug resistant cancer and eliminate malignant cells. Indeed, we have recently shown that programmed necrosis, termed necroptosis, could be triggered to induce cell death in a subgroup of primary acute lymphoblastic leukemia (ALL) including highly refractory relapsed cases. In this review we focus on molecular mechanisms that drive drug resistance in ALL of childhood and discuss the potential of necroptosis activation to eradicate resistant disease.
format Online
Article
Text
id pubmed-6433701
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64337012019-04-02 Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia Mezzatesta, Caterina Bornhauser, Beat C. Front Cell Dev Biol Cell and Developmental Biology Escape from chemotherapy-induced apoptosis is a hallmark of drug resistance in cancer. The recent identification of alternative programmed cell death pathways opens up for possibilities to circumvent the apoptotic blockade in drug resistant cancer and eliminate malignant cells. Indeed, we have recently shown that programmed necrosis, termed necroptosis, could be triggered to induce cell death in a subgroup of primary acute lymphoblastic leukemia (ALL) including highly refractory relapsed cases. In this review we focus on molecular mechanisms that drive drug resistance in ALL of childhood and discuss the potential of necroptosis activation to eradicate resistant disease. Frontiers Media S.A. 2019-03-19 /pmc/articles/PMC6433701/ /pubmed/30941349 http://dx.doi.org/10.3389/fcell.2019.00040 Text en Copyright © 2019 Mezzatesta and Bornhauser. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Mezzatesta, Caterina
Bornhauser, Beat C.
Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
title Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
title_full Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
title_fullStr Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
title_full_unstemmed Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
title_short Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
title_sort exploiting necroptosis for therapy of acute lymphoblastic leukemia
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433701/
https://www.ncbi.nlm.nih.gov/pubmed/30941349
http://dx.doi.org/10.3389/fcell.2019.00040
work_keys_str_mv AT mezzatestacaterina exploitingnecroptosisfortherapyofacutelymphoblasticleukemia
AT bornhauserbeatc exploitingnecroptosisfortherapyofacutelymphoblasticleukemia